Go Pro

Cardiol Therapeutics (CRDL) Earnings Date, Estimates & Call Transcripts

Cardiol Therapeutics logo
$1.86 -0.03 (-1.33%)
As of 08/21/2026 04:00 PM Eastern

Cardiol Therapeutics Earnings Summary

Cardiol Therapeutics announced Q2 2026 earnings on August 13, 2026, reporting an EPS of -$0.04, which beat analysts' consensus estimates of -$0.09 by $0.05. With a trailing EPS of -$0.25, Cardiol Therapeutics' earnings are expected to grow next year, from ($0.24) to ($0.21) per share.

Q2 2026 Earnings Resources

Latest Q2
Earnings Date
Aug. 13Estimated
Consensus EPS
(Aug. 13)
-$0.09
Actual EPS
(Aug. 13)
-$0.04 Beat By $0.05
Get Cardiol Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiol Therapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

CRDL Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Cardiol Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20263-$0.13-$0.06-$0.09
Q2 20264-$0.15-$0.07-$0.10
Q3 20264-$0.13-$0.06-$0.09
Q4 20264-$0.15-$0.06-$0.10

Cardiol Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026-$0.09-$0.04+$0.05-$0.04--
5/11/2026Q1 2026-$0.07-$0.07--$0.07--
3/30/2026Q4 2025-$0.09-$0.05+$0.04-$0.05--
11/13/2025Q3 2025-$0.09-$0.09--$0.09--
8/14/2025Q2 2025-$0.11-$0.07+$0.04-$0.07--
3/31/2025Q4 2024-$0.08-$0.07+$0.01-$0.07--

Cardiol Therapeutics Earnings - Frequently Asked Questions

Cardiol Therapeutics (NASDAQ:CRDL) last announced its quarterly earning data on Thursday, August 13, 2026. Learn more on CRDL's earnings history.

In the previous quarter, Cardiol Therapeutics (NASDAQ:CRDL) reported ($0.04) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.09) by $0.05. Learn more on analysts' earnings estimate vs. CRDL's actual earnings.

Cardiol Therapeutics (NASDAQ:CRDL) has a recorded net income of -$24.20 million. CRDL has generated -$0.25 earnings per share over the last four quarters.

Cardiol Therapeutics' earnings are expected to grow from ($0.24) per share to ($0.21) per share in the next year.


Earnings data for NASDAQ:CRDL is sourced from Fiscal.ai, with the most recent quarter reported on 8/13/2026. New results are added as companies report their earnings.
From Our Partners